A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

NCT06929624 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: SHR-A1912 Injection
DRUG: Rituximab Injection
DRUG: Gemcitabine Hydrochloride for Injection
DRUG: Oxaliplatin Injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.